Loteprednol etabonate nanostructured lipid carriers for enhanced ocular bioavailability
Colloids and Surfaces B: Biointerfaces · 2026-08 · 264 · 115661
DOI: 10.1016/j.colsurfb.2026.115661 ↗Kurz gefasst
Fachartikel in der Zeitschrift Colloids and Surfaces B: Biointerfaces, 2026-08. Verfasst von Suraj Fanse und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA. Hauptthemen laut MEDLINE: Loteprednol Etabonate, Lipids, Drug Carriers, Nanostructures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
Loteprednol etabonate (LTP), a corticosteroid approved for management of post-operative ocular inflammation and dry eye symptoms, suffers from limited ocular bioavailability and high dosing frequency in its current marketed form, Lotemax® suspension. The current study reports the development and optimization of a novel nanostructured lipid carrier (NLC) system for LTP, designed to overcome these limitations through enhanced corneal penetration, sustained release, and improved therapeutic efficacy. Excipient screening assessment identified Gelucire 44/14, Miglyol 829, and Tween 80 as optimal solid lipid, liquid lipid, and surfactant, respectively, for LTP-NLC formulation. LTP-NLCs incorporating Transcutol® P as a permeation enhancer, and LTP-NLCs loaded into gellan gum-based ion-sensitive in situ gels, were systematically investigated. A Box-Behnken design enabled optimization of formulation variables, achieving ∼200 nm particle size with > 98% entrapment at 0.5% w/w drug load through precise control of lipid/surfactant balance and homogenization parameters. The optimized LTP-NLCs demonstrated excellent physicochemical stability (>3 months), amorphous drug dispersion within NLCs, and suitable rheological behavior. In vitro drug release studies (USP App IV) and ex vivo permeation studies across corneal and conjunctival tissues showed sustained release for LTP-NLCs compared to Lotemax®, with superior transcorneal permeation and minimal conjunctival loss. Incorporation of LTP-NLCs into gellan gum loaded in situ gels increased ocular retention but reduced permeability due to high viscosity. On the other hand, Transcutol® P markedly improved the transcorneal flux of LTP-NLCs and enhanced cellular uptake in human corneal epithelial cells. All formulations were non-irritant (HET-CAM), biocompatible, and maintained > 80% cell viability. Overall, the present work introduces a very promising LTP-NLC platform with demonstrated superiority over existing therapies, offering a strategy for enhancing ocular drug delivery, reducing dosing burden, and improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA.
- University of Connecticut, College of Liberal Arts and Sciences, Storrs, CT 06269, USA.
- University of Connecticut, School of Pharmacy, Storrs, CT 06269, USA. Electronic address: d.burgess@uconn.edu.
Zitieren
APA
Fanse, S., Maurus, K., Bhorkade, S., & Burgess, D. J. (2026). Loteprednol etabonate nanostructured lipid carriers for enhanced ocular bioavailability. Colloids and Surfaces B: Biointerfaces, 264, 115661. https://doi.org/10.1016/j.colsurfb.2026.115661
Vancouver
Fanse S, Maurus K, Bhorkade S, Burgess DJ. Loteprednol etabonate nanostructured lipid carriers for enhanced ocular bioavailability. Colloids and Surfaces B: Biointerfaces. 2026;264:115661. doi:10.1016/j.colsurfb.2026.115661
BibTeX
@article{Fanse2026,
author = {Fanse, Suraj and Maurus, Kellen and Bhorkade, Saurabh and Burgess, Diane J},
title = {Loteprednol etabonate nanostructured lipid carriers for enhanced ocular bioavailability},
journal = {Colloids and Surfaces B: Biointerfaces},
year = {2026},
volume = {264},
pages = {115661},
doi = {10.1016/j.colsurfb.2026.115661}
}
EUVIMED